 |
|
 |
- March 10, 2010 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"New Insights in Diabetic Retinopathy"Dr. Filiberto Altomare (biography)
English - 2003-10-31 - 40 minutes
|
 | (31 slides) |
Summary :
The underlying pathogenesis of diabetic retinopathy has long been thought of as being primarily vascular in nature, but there is growing evidence that there are not only vascular but neuronal changes (1, 2) involved.
A better understanding of the molecular biology of the ocular angiogenesis pathway has led to the development of new therapeutic targets. For example, inhibition of vascular endothelial growth factor (VEGF) receptor kinase activity was found to prevent retinal neovascularization (3). Furthermore, ACE inhibition was found to reduce VEGF overexpression and hyperpermeability seen in diabetic retinopathy (4).
This presentation will review the latest understanding of the pathogenesis and advances in treatment of diabetic retinopathy.
Copyright © 2003 E-MedHosting.com Inc
Learning objectives :
The participant will get a new understanding of the pathogenesis of diabetic retinopathy and learn about advances in its treatment.
Conclusion:
- Diabetic retinopathy is a disease that includes neurodegenerative as well as vascular pathologies. Therefore, vision loss can be attributed to neuronal dysfunction and vascular abnormalities.
- Great acheivements in the understanding of the molecular biology of angiogenesis have occurred. This has permitted the identification of novel targets in the management of diabetic retinopathy.
- A number of clinical trials are underway, the outcome of which will initiate a new era whereby diabetic retinopathy is managed pharmacologically, rather than with laser photocoagulation.
Bibliographic references :
1. Scott TM, Foote J, Peat B, Galway G. “Vascular and neural changes in the rat optic nerve following induction of diabetes with streptozotocin.” J Anat. 1986 Feb;144:145-52.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2961719&dopt=Abstract
2. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. “Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.” J Clin Invest. 1998 Aug 15;102(4):783-91.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9710447&dopt=Abstract
3. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. “Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.” Am J Pathol. 2000 Feb;156(2):697-707.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10666398&dopt=Abstract
4. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME. “Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.” Diabetologia. 2000 Nov;43(11):1360-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11126403&dopt=Abstract
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
